Altogether, these promising preclinical results underscore the potential of targeting S100A9 in combination with standard-of-care chemotherapy to significantly improve the clinical efficacy of cisplatin-based chemotherapy and extend the overall survival of SCLC patients. This evidence concerns the gene S100A9 and small cell lung carcinoma.